Coriolis Pharma
Martinsried, Germany
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Coriolis Pharma
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Martinsried, Germany
- Modalities
- Biologics, Drug Product Formulation, Analytical Services, mAb, ATMPs/Cell & Gene Therapy, Oligonucleotide
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Coriolis Pharma
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesBiologics, Drug Product Formulation, Analytical Services, mAb, ATMPs/Cell & Gene Therapy, Oligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (6 modalities)
Recent News 10 articles
Coriolis Pharma launches U.S. entity alongside innovative drug product platform service offerings for monoclonal antibodies - PR Newswire
Coriolis Pharma announces plans to invest $10 million, creating 50 jobs in Morrisville - Wake County Government (.gov)
Coriolis Pharma Opens New Laboratory in Morrisville, NC - Contract Pharma
Coriolis Pharma Partners with Frontier Biosolutions - Contract Pharma
CPHI Pharma Awards 2025 finalists announced - European Pharmaceutical Review
Coriolis Pharma’s ATMP Facility, Martinsried, Germany - Pharmaceutical Technology
Coriolis Pharma Opens New Site in North Carolina - Contract Pharma
KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma - Business Wire
ESTEVE CDMO commences $15.5m expansion of US facility - Pharmafile
11 private equity deals sampling the pharma sector - pehub.com
Frequently Asked Questions About Coriolis Pharma
What is Coriolis Pharma's CDMO Signal Score?
Coriolis Pharma has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Coriolis Pharma for a manufacturing program?
Use the free AI matchmaker to compare Coriolis Pharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
Biologics, mAb, Cell Therapy, Gene Therapy (AAV), Oligonucleotide, mRNA, Small Molecule
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 85.6
Oligonucleotide, Biologics, AAV
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 82.5
mRNA, Oligonucleotide, Biologics
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.4
mRNA, Oligonucleotide, Biologics
Aurigene Pharmaceutical Services
Hyderabad, IN
Signal Score: 63.0
Oligonucleotide, Biologics